Glucotrack announces 1-for-20 reverse stock split
RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ:GCTK), a medical device company specializing in diabetes care technology, has announced a 1-for-20 reverse stock split of its issued and outstanding common ...
drugdeliverybusiness10d
Glucotrack completes first-in-human continuous blood glucose monitor implant study
Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...
Business Insider10d
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and ...
Nasdaq10d
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...
Morningstar10d
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
(“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the ...